- Home
- RVI vs IMMX Comparison
RVI vs IMMX Comparison
Compare RVI & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RVI | IMMX |
|---|---|---|
| Founded | N/A | 2014 |
| Country | | United States |
| Employees | N/A | N/A |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 778.2M | 716.2M |
| IPO Year | 2025 | 2021 |
Fundamental Metrics
Financial Performance| Metric | RVI | IMMX |
|---|---|---|
| Price | $26.54 | $13.97 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $19.20 |
| AVG Volume (30 Days) | 141.6K | ★ 1.5M |
| Earning Date | N/A | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $22.21 | $1.94 |
| 52 Week High | $77.39 | $15.10 |
Technical Indicators
Market Signals| Indicator | RVI | IMMX |
|---|---|---|
| Relative Strength Index (RSI) | 43.71 | 67.77 |
| Support Level | $26.15 | $7.96 |
| Resistance Level | $27.95 | $15.10 |
| Average True Range (ATR) | 0.83 | 0.78 |
| MACD | 0.06 | 0.03 |
| Stochastic Oscillator | 18.50 | 72.82 |
Price Performance
Historical ComparisonAbout RVI Robinhood Ventures Fund I Common Shares of Beneficial Interest
Robinhood Ventures Fund I is a closed-end investment company. The investment objective, the Fund will mainly invest, under normal circumstances, in a concentrated portfolio generally consisting of ten or more private companies that, in the view, are growing companies at the frontiers of their respective sectors and industries. The Fund operates as a single segment.
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.